Company Profile
ADMA Biologics Stock Price, News & Analysis
Company overview
Business overview
ADMA Biologics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, ADMA Biologics is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
ADMA Biologics follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, ADMA Biologics sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
ADMA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
ADMA Biologics's catalysts are ASCENIV, BIVIGAM, and plasma-product manufacturing execution, with the stock mostly following commercial scale and supply discipline. The company moves on reliable commercialization more than on binary news.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
Source: ADMA Biologics
- 02
- 03
ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026
Source: ADMA Biologics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.